TY - JOUR
T1 - Immunohistochemical biomarkers and FDG uptake on PET/CT in head and neck squamous cell carcinoma
AU - Rasmussen, Gregers Brünnich
AU - Vogelius, Ivan R.
AU - Rasmussen, Jacob H
AU - Schumaker, Lisa
AU - Ioffe, Olga
AU - Cullen, Kevin
AU - Fischer, Barbara Malene
AU - Therkildsen, Marianne Hamilton
AU - Specht, Lena
AU - Bentzen, Søren M
PY - 2015/10/21
Y1 - 2015/10/21
N2 - Background. There is an exciting complementarity between the spatial resolution provided by molecular imaging of a single, often unspecific, biomarker on one hand and the more detailed biological profile achievable from a diagnostic biopsy using a panel of immunohistochemical (IHC) markers on the other. A number of previous studies have shown a relationship between glucose transport protein expression and 18F-Fludeoxyglucose (FDG) PET uptake. Here, FDG uptake is analyzed in relation to expression of a selected panel of IHC cancer biomarkers in head and neck squamous cell carcinomas (HNSCC).Material and methods. IHC staining for Bcl-2, β-tubulin-1 and 2, p53, EGFR, Ki-67, glutathione-S-transferase-π and p16 was performed on formalin-fixed paraffin embedded diagnostic biopsies from 102 HNSCC cases treated at Rigshospitalet during 2005-2009. The proportion of positive cells was used for analyses, except p16, which was scored according to EORTC guidelines. In all cases, maximal FDG standardized uptake value (SUV) metrics were extracted for the primary tumor, TSUVmax. Univariate linear regression and multiple linear regression of TSUVmax versus IHC markers were performed.Results. In univariate analyses, TSUVmax showed negative associations with Bcl-2 (p = 0.002) and p16 (p = 0.005) indices and positive association with β-tubulin-1 index (p = 0.003). On multivariate analysis, TSUVmax remained associated with β-tubulin-1 (p = 0.009), Bcl-2 (p = 0.03) and p16 (p = 0.03). All correlations had r-squared < 0.3.Conclusion. Statistically significant correlations were observed between the expression of IHC biomarkers and maximum FDG uptake in the primary tumor.
AB - Background. There is an exciting complementarity between the spatial resolution provided by molecular imaging of a single, often unspecific, biomarker on one hand and the more detailed biological profile achievable from a diagnostic biopsy using a panel of immunohistochemical (IHC) markers on the other. A number of previous studies have shown a relationship between glucose transport protein expression and 18F-Fludeoxyglucose (FDG) PET uptake. Here, FDG uptake is analyzed in relation to expression of a selected panel of IHC cancer biomarkers in head and neck squamous cell carcinomas (HNSCC).Material and methods. IHC staining for Bcl-2, β-tubulin-1 and 2, p53, EGFR, Ki-67, glutathione-S-transferase-π and p16 was performed on formalin-fixed paraffin embedded diagnostic biopsies from 102 HNSCC cases treated at Rigshospitalet during 2005-2009. The proportion of positive cells was used for analyses, except p16, which was scored according to EORTC guidelines. In all cases, maximal FDG standardized uptake value (SUV) metrics were extracted for the primary tumor, TSUVmax. Univariate linear regression and multiple linear regression of TSUVmax versus IHC markers were performed.Results. In univariate analyses, TSUVmax showed negative associations with Bcl-2 (p = 0.002) and p16 (p = 0.005) indices and positive association with β-tubulin-1 index (p = 0.003). On multivariate analysis, TSUVmax remained associated with β-tubulin-1 (p = 0.009), Bcl-2 (p = 0.03) and p16 (p = 0.03). All correlations had r-squared < 0.3.Conclusion. Statistically significant correlations were observed between the expression of IHC biomarkers and maximum FDG uptake in the primary tumor.
KW - Biomarkers, Tumor
KW - Carcinoma, Squamous Cell
KW - Fluorodeoxyglucose F18
KW - Glutathione Transferase
KW - Head and Neck Neoplasms
KW - Humans
KW - Immunohistochemistry
KW - Ki-67 Antigen
KW - Multimodal Imaging
KW - Multivariate Analysis
KW - Neoplasm Proteins
KW - Positron-Emission Tomography
KW - Proto-Oncogene Proteins c-bcl-2
KW - Radiopharmaceuticals
KW - Receptor, Epidermal Growth Factor
KW - Tomography, X-Ray Computed
KW - Tubulin
KW - Tumor Suppressor Protein p53
U2 - 10.3109/0284186X.2015.1062539
DO - 10.3109/0284186X.2015.1062539
M3 - Journal article
C2 - 26256482
SN - 1100-1704
VL - 54
SP - 1408
EP - 1415
JO - Acta Oncologica, Supplement
JF - Acta Oncologica, Supplement
IS - 9
ER -